Skip to main content
Evidence Snapshot

Cathepsin S

CHEMBL2954 SINGLE PROTEIN Homo sapiens
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T20:44:27Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL2954
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Cathepsin S as ChEMBL target CHEMBL2954, mapped to UniProt P25774. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Cathepsin S
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL2954
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P25774
Cathepsin S
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Cathepsin S matters

As of 2026-09-13

Cathepsin S is reviewed as Cathepsin S (UniProt P25774); Cathepsin S shows clinical signal disease relevance led by Sjogren syndrome. 2 more disease programs remain visible in the same review block.; 1 linked drug keep this evidence frame grounded.; the current evidence base includes 4 approved drugs, 3068 compounds, and 307 assays, with lead potency reaching pChEMBL 10.8.

Disease context
Sjogren syndrome

Cathepsin S shows clinical signal disease relevance led by Sjogren syndrome. 2 more disease programs remain visible in the same review block. 1 linked drug keep the rationale reviewable. 2 additional disease programs remain visible in the same card. Linked drugs include PETESICATIB.

Start review with Sjogren syndrome because it currently carries clinical signal support. Linked drugs include PETESICATIB. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Clinical signal 1 linked drug
Activity base
Portfolio and assay base

ChEMBL currently tracks 4 approved drugs, 3068 compounds, and 307 assays for this target. The dominant activity type is IC50. CHEMBL5573840 is the current potency anchor at pChEMBL 10.8.

Use CHEMBL5573840 as the tractability anchor when discussing potency (pChEMBL 10.8).

Activity source · ChEMBL 36 via Core Engine
4 approved pChEMBL 10.8
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Cathepsin S matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt P25774, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need to see why Sjogren syndrome is currently treated as clinical signal support.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

3068
Total Compounds
307
Total Assays
4
Approved Drugs
IC50: 2382.0, KI: 852.0, EC50: 3.0, KD: 66.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL5573840
 10.8 Ki —
No preferred name
CHEMBL3651506
 10.5 IC50 —
No preferred name
CHEMBL3651502
 10.3 IC50 —
No preferred name
CHEMBL3651503
 10.2 IC50 —
No preferred name
CHEMBL3651507
 10.2 IC50 —

Approved Drugs

Structure Compound First Approval
SIMEPREVIR
CHEMBL501849
 2013
BOCEPREVIR
CHEMBL218394
 2011
TELAPREVIR
CHEMBL231813
 2011
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T20:44:27Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL2954